Johnson & Johnson's Stelara Approved for Pediatric Ulcerative Colitis
The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Johnson & Johnson’s (JNJ:NYSE) drug Stelara (ustekinumab), allowing its use in pediatric patients aged two years and older with moderately to severely active ulcerative colitis. This approval is based on clinical study data demonstrating the efficacy of Stelara in treating this condition. The expansion into a younger patient demographic could increase demand for the drug, potentially boosting J&J’s revenue from this product line. The decision reflects ongoing efforts by pharmaceutical companies to address unmet medical needs and expand therapeutic options across age groups.
Tickers: $JNJ